Sinocare Unveils Integrated Solutions for Chronic Disease Management at EASD 2026

Sinocare Introduces Integrated Solutions for Chronic Disease Management at EASD 2026

Sinocare, a pioneer in glucose monitoring devices and leader in chronic disease management solutions, revealed its innovative portfolio at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD 2026) from September 28 to October 2 in Milan. This gathering brought together leading experts and innovators in the diabetes field, setting the scene for Sinocare's array of products designed for home care, community pharmacies, and hospitals.

Comprehensive Solutions Designed for Multiple Care Environments

Sinocare's latest offerings reflect a commitment to enhancing chronic disease management through accessible, integrated technology. For home users, the newly introduced Safe AQ max II blood glucose monitoring system provides results in just five seconds. It features Bluetooth data synchronization and allows users to tag their measurements before and after meals, making diabetes monitoring seamless and user-friendly. The KUG-11 meter adds more versatility by enabling “three-in-one” testing for glucose, uric acid, and ketones. Pet owners will also appreciate the GV-100 veterinary system, which aids in home blood glucose monitoring for dogs and cats.

For community pharmacies, Sinocare has developed the iCARE-1300, a portable multifunctional analyzer capable of automated testing for nearly 100 parameters, including blood glucose levels, lipid profiles, HbA1c, and renal function. This device ensures results are delivered quickly, within three to fifteen minutes, thereby empowering pharmacies to enhance chronic disease detection and risk assessment. Furthermore, Sinocare's Health Station model is designed to elevate pharmacy capabilities in evaluating patients for potential chronic diseases.

In the hospital setting, Sinocare presented the AGEscan, a fluorescence detector for advanced glycation end-products (AGE) that allows for non-invasive detection, eliminating the need for blood extraction. This innovation facilitates early risk assessment, crucial for timely intervention. Additionally, the Safe AQ 8000 smart blood glucose management system connects seamlessly with hospital information systems, integrating data from glucose meters and continuous glucose monitoring systems (CGM) via the Doctor Web Portal. This connectivity enables bedside testing and enhances patient monitoring, ensuring healthcare professionals can provide comprehensive care.

A Commitment to Global Health

Sinocare envisions a healthcare landscape where effective chronic disease management is accessible worldwide, and their latest portfolio embodies this vision. By intertwining early detection, regular monitoring, and comprehensive long-term management, their solutions aim to empower patients and healthcare providers alike.

Founded in 2002, Sinocare holds the distinction of being the first publicly listed blood glucose meter company in China and stands as the country's largest glucose monitoring device manufacturer, boasting over 780 authorized patents and nine R&D and manufacturing centers globally. With services reaching over 25 million users in 187 countries, Sinocare ranks among the top four glucose meter companies worldwide. Their focus on “Biosensors + AI + Healthcare” positions them to develop holistic solutions for chronic disease management.

For further insights into Sinocare's innovative products and their commitment to improving global health outcomes, visit www.sinocare.com/en.